These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 37242487)
1. Diosgenin and Monohydroxy Spirostanol from Shalayel MHF; Al-Mazaideh GM; Alanezi AA; Almuqati AF; Alotaibi M Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242487 [TBL] [Abstract][Full Text] [Related]
2. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach. Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395 [TBL] [Abstract][Full Text] [Related]
3. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies. Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960 [TBL] [Abstract][Full Text] [Related]
4. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2. Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808 [TBL] [Abstract][Full Text] [Related]
5. Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2. Martiniano B J Mol Model; 2021 Mar; 27(4):105. PubMed ID: 33686576 [TBL] [Abstract][Full Text] [Related]
7. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505 [TBL] [Abstract][Full Text] [Related]
8. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Medina PJ; Goodin S Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986 [TBL] [Abstract][Full Text] [Related]
9. Unveiling promising phytocompounds from Moringa oleifera as dual inhibitors of EGFR Masudur Rahman Munna M; Touki Tahamid Tusar M; Sajnin Shanta S; Hossain Ahmed M; Sarafat Ali M J Genet Eng Biotechnol; 2024 Sep; 22(3):100406. PubMed ID: 39179328 [TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model. Nakayama A; Takagi S; Yusa T; Yaguchi M; Hayashi A; Tamura T; Kawakita Y; Ishikawa T; Ohta Y J Cancer; 2013; 4(7):557-65. PubMed ID: 23983820 [TBL] [Abstract][Full Text] [Related]
12. Identification of phytocompounds as potent inhibitors of sodium/glucose cotransporter-2 leading to diabetes treatment. Swargiary A; Daimari M; Swargiary A; Biswas A; Brahma D; Singha H J Biomol Struct Dyn; 2024 Feb; ():1-14. PubMed ID: 38379332 [TBL] [Abstract][Full Text] [Related]
13. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach. Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911 [TBL] [Abstract][Full Text] [Related]
14. Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2. Balbuena-Rebolledo I; Padilla-Martínez II; Rosales-Hernández MC; Bello M Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451888 [TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives. Elkamhawy A; Son S; Lee HY; El-Maghrabey MH; Hamd MAE; Alshammari SO; Abdelhameed AA; Alshammari QA; Abdeen A; Ibrahim SF; Mahdi WA; Alshehri S; Alnajjar R; Choi WJ; Al-Karmalawy AA; Lee K Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678540 [TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report. Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069 [TBL] [Abstract][Full Text] [Related]